Baird Medical Showcases Groundbreaking MWA Innovations at NASIT 2025
Baird Medical (NASDAQ: BDMD) made a notable presence at the 2025 North American Society for Interventional Thyroidology (NASIT) conference, showcasing its advanced microwave ablation (MWA) technology for thyroid treatment. The company's exhibit generated significant interest, facilitating meaningful discussions with healthcare professionals about minimally invasive thyroid therapies.
A key highlight was a keynote presentation by Dr. Emad Kandil from Tulane University School of Medicine, who presented case studies and clinical data demonstrating MWA's advantages, including reduced procedure times, fewer complications, and improved patient outcomes. The presentation garnered substantial attention and sparked engaging discussions, underlining the industry's interest in MWA technology.
Through the conference, Baird Medical reinforced its position in advancing patient care through innovation and strengthened its collaborations with medical professionals in the field of minimally invasive thyroid treatments.
Baird Medical (NASDAQ: BDMD) ha fatto una presenza notevole alla conferenza della North American Society for Interventional Thyroidology (NASIT)tecnologia di ablazione a microonde (MWA) per il trattamento della tiroide. Lo stand dell'azienda ha suscitato un interesse significativo, facilitando discussioni significative con professionisti della salute sulle terapie tiroidee minimamente invasive.
Un momento chiave è stato l'intervento principale del Dr. Emad Kandil della Tulane University School of Medicine, che ha presentato casi studio e dati clinici dimostrando i vantaggi della MWA, inclusi tempi di procedura ridotti, minori complicazioni e migliori risultati per i pazienti. La presentazione ha attirato notevole attenzione e ha stimolato discussioni coinvolgenti, sottolineando l'interesse del settore per la tecnologia MWA.
Durante la conferenza, Baird Medical ha rafforzato la sua posizione nel migliorare la cura dei pazienti attraverso l'innovazione e ha consolidato le sue collaborazioni con professionisti medici nel campo dei trattamenti tiroidei minimamente invasivi.
Baird Medical (NASDAQ: BDMD) tuvo una presencia notable en la conferencia de la North American Society for Interventional Thyroidology (NASIT) de 2025, mostrando su avanzada tecnología de ablación por microondas (MWA) para el tratamiento de la tiroides. La exhibición de la empresa generó un interés significativo, facilitando discusiones relevantes con profesionales de la salud sobre terapias tiroideas mínimamente invasivas.
Un punto destacado fue la presentación principal del Dr. Emad Kandil de la Tulane University School of Medicine, quien presentó estudios de casos y datos clínicos que demostraban las ventajas de la MWA, incluyendo tiempos de procedimiento reducidos, menos complicaciones y mejores resultados para los pacientes. La presentación atrajo una atención sustancial y generó discusiones interesantes, subrayando el interés de la industria en la tecnología MWA.
A lo largo de la conferencia, Baird Medical reforzó su posición en la mejora de la atención al paciente a través de la innovación y fortaleció sus colaboraciones con profesionales médicos en el campo de los tratamientos tiroideos mínimamente invasivos.
Baird Medical (NASDAQ: BDMD)는 2025년 북미 개입 갑상선학회(NASIT) 컨퍼런스에서 주목할 만한 존재감을 나타내며, 갑상선 치료를 위한 마이크로웨이브 절제술(MWA) 기술을 선보였습니다. 회사의 전시는 상당한 관심을 불러일으켰으며, 의료 전문가들과의 의미 있는 논의를 촉진하여 최소 침습 갑상선 치료법에 대해 논의할 수 있었습니다.
주요 하이라이트는 Tulane University School of Medicine의 Emad Kandil 박사가 발표한 기조 연설로, MWA의 장점을 입증하는 사례 연구와 임상 데이터를 제시했습니다. 여기에는 절차 시간 단축, 합병증 감소 및 환자 결과 개선이 포함됩니다. 발표는 상당한 주목을 받았고, MWA 기술에 대한 업계의 관심을 강조하는 흥미로운 논의를 이끌어냈습니다.
컨퍼런스 기간 동안 Baird Medical은 혁신을 통해 환자 치료를 발전시키려는 입장을 강화하고, 최소 침습 갑상선 치료 분야에서 의료 전문가들과의 협력을 강화했습니다.
Baird Medical (NASDAQ: BDMD) a fait une présence remarquable à la conférence de la North American Society for Interventional Thyroidology (NASIT) en 2025, présentant sa technologie d'ablation par micro-ondes (MWA) avancée pour le traitement de la thyroïde. Le stand de l'entreprise a suscité un intérêt significatif, facilitant des discussions significatives avec des professionnels de la santé sur les thérapies thyroïdiennes peu invasives.
Un moment clé a été la présentation principale par le Dr. Emad Kandil de la Tulane University School of Medicine, qui a présenté des études de cas et des données cliniques démontrant les avantages de la MWA, y compris des temps de procédure réduits, moins de complications et de meilleurs résultats pour les patients. La présentation a attiré une attention considérable et a suscité des discussions engageantes, soulignant l'intérêt de l'industrie pour la technologie MWA.
Tout au long de la conférence, Baird Medical a renforcé sa position dans l'avancement des soins aux patients grâce à l'innovation et a renforcé ses collaborations avec des professionnels médicaux dans le domaine des traitements thyroïdiens peu invasifs.
Baird Medical (NASDAQ: BDMD) machte eine bemerkenswerte Präsenz auf der Konferenz der North American Society for Interventional Thyroidology (NASIT) im Jahr 2025, bei der sie ihre fortschrittliche Mikrowellen-Ablationstechnologie (MWA) zur Behandlung der Schilddrüse präsentierte. Der Stand des Unternehmens erregte erhebliches Interesse und erleichterte bedeutungsvolle Diskussionen mit Fachleuten des Gesundheitswesens über minimal-invasive Schilddrüsen-Therapien.
Ein Höhepunkt war die Hauptpräsentation von Dr. Emad Kandil von der Tulane University School of Medicine, der Fallstudien und klinische Daten vorlegte, die die Vorteile der MWA demonstrierten, darunter verkürzte Verfahrenszeiten, weniger Komplikationen und verbesserte Patientenergebnisse. Die Präsentation erlangte beträchtliche Aufmerksamkeit und entzündete anregende Diskussionen, was das Interesse der Branche an der MWA-Technologie unterstrich.
Im Verlauf der Konferenz festigte Baird Medical seine Position in der Verbesserung der Patientenversorgung durch Innovation und stärkte die Zusammenarbeit mit medizinischen Fachkräften im Bereich der minimal-invasiven Schilddrüsenbehandlungen.
- None.
- None.
Baird Medical's exhibit drew strong interest, sparking in-depth discussions with clinicians about the future of minimally invasive thyroid therapies. The Company provided expert insights into MWA's efficacy and safety in treating thyroid nodules, addressing key concerns from physicians. Hands-on demonstrations allowed attendees to experience the technology's precision and efficiency firsthand, further reinforcing Baird Medical's leadership in the field.
A highlight of the conference was a keynote presentation by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine. Dr. Kandil shared compelling case studies and clinical data demonstrating MWA's role as a safe, effective, and minimally invasive alternative to traditional thyroid surgery. He emphasized key benefits, including reduced procedure times, fewer complications, and improved patient outcomes. The session attracted a large audience and ignited dynamic discussions, highlighting the industry's strong interest in MWA technology and providing robust support for Baird Medical's vision of minimally invasive treatment.
Baird Medical's presence at NASIT 2025 reaffirmed its commitment to advancing patient care through innovation. By deepening collaborations with medical professionals, the Company continues to drive progress in minimally invasive thyroid treatments. Looking ahead, Baird Medical aims to leverage further research breakthroughs and strategic partnerships to enhance treatment options for patients and propel advancements in minimally invasive therapies.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-groundbreaking-mwa-innovations-at-nasit-2025-302366242.html
SOURCE BDMD
FAQ
What innovations did Baird Medical (BDMD) showcase at NASIT 2025?
What clinical benefits of BDMD's MWA technology were presented at NASIT 2025?
Who was the keynote speaker for Baird Medical at NASIT 2025?
How did BDMD's participation in NASIT 2025 compare to their 2024 appearance?
